PURPOSE OF REVIEW: To review recent human trials assessing cholesterol-lowering agents in nonalcoholic fatty liver disease (NAFLD). RECENT FINDINGS: Four randomized controlled trials (RCTs) assessed statins in NAFLD. In the only RCT with post-treatment biopsy, simvastatin did not change liver histology. In the remaining RCTs, atorvastatin was well tolerated, significantly improved radiological/biochemical markers of steatosis and plasma lipids, with neutral effects on glucose metabolism; in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study, atorvastatin reduced incident cardiovascular disease compared with both untreated NAFLD patients and with statin-treated patients without NAFLD. Ezetimibe was evaluated in two uncontrolled trials and two RCTs, consistently improving liver histology and plasma lipids, whereas glucose metabolism was generally unaffected; however, HbA1c increased with ezetimibe in one RCT. SUMMARY: From the analysis of available trials, it emerges that cholesterol-lowering agents may considerably benefit NAFLD patients. Statins are well tolerated, and atorvastatin improved surrogate markers of liver disease, whereas their effect on liver histology is unknown. Furthermore, the GREACE study was the first trial to show clinical benefit from the use of a pharmacological agent in NAFLD. Ezetimibe improved liver histology. The benefit of combination therapy, as well as the safety on glucose metabolism, need further evaluation.

Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update.

CASSADER, Maurizio;GAMBINO, Roberto
2011-01-01

Abstract

PURPOSE OF REVIEW: To review recent human trials assessing cholesterol-lowering agents in nonalcoholic fatty liver disease (NAFLD). RECENT FINDINGS: Four randomized controlled trials (RCTs) assessed statins in NAFLD. In the only RCT with post-treatment biopsy, simvastatin did not change liver histology. In the remaining RCTs, atorvastatin was well tolerated, significantly improved radiological/biochemical markers of steatosis and plasma lipids, with neutral effects on glucose metabolism; in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study, atorvastatin reduced incident cardiovascular disease compared with both untreated NAFLD patients and with statin-treated patients without NAFLD. Ezetimibe was evaluated in two uncontrolled trials and two RCTs, consistently improving liver histology and plasma lipids, whereas glucose metabolism was generally unaffected; however, HbA1c increased with ezetimibe in one RCT. SUMMARY: From the analysis of available trials, it emerges that cholesterol-lowering agents may considerably benefit NAFLD patients. Statins are well tolerated, and atorvastatin improved surrogate markers of liver disease, whereas their effect on liver histology is unknown. Furthermore, the GREACE study was the first trial to show clinical benefit from the use of a pharmacological agent in NAFLD. Ezetimibe improved liver histology. The benefit of combination therapy, as well as the safety on glucose metabolism, need further evaluation.
2011
22
489
496
Musso G; Cassader M; Gambino R.
File in questo prodotto:
File Dimensione Formato  
Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease_an update.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 184.75 kB
Formato Adobe PDF
184.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Curr Opin Lipid_2011.pdf

Open Access dal 27/02/2014

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 454.99 kB
Formato Adobe PDF
454.99 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/97940
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 42
social impact